PRA Health Sciences

PRA Health Sciences

PRA Health Sciences was founded in 2000 and is led by Colin Shannon as President and CEO. The firm provides outsourced clinical development services to drug and device companies, operating as a contract research organization (CRO) rather than a traditional asset manager or family office. Its wealth origin is not publicly disclosed as a family office; it operates as a publicly traded entity before being taken private. The firm's strategy centers on managing Phase I through Phase IV clinical trials across therapeutic areas including oncology, central nervous system disorders, and cardiovascular disease. Its deployment focuses on building global trial infrastructure, including a network of early-phase clinical units and data management platforms. Known geographies include North America, Europe, and Asia-Pacific, with operational hubs in more than 100 countries. Total deployment in clinical infrastructure remains undisclosed, as does team size. The firm maintains a formal governance structure typical of a mid-sized CRO, with a board of directors and executive leadership; no philanthropic wing or investment office is publicly documented. In 2021, PRA Health Sciences was acquired by ICON plc for about $12 billion (per press releases, 2021). PRA Health Sciences' structural differentiator is its hybrid model as both a clinical services provider and an asset-light manager of drug development programs — a design that finances trials on behalf of sponsors while carrying minimal balance-sheet risk compared to biotech firms.